1Holloway WJ,Palmer D.Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections[J].Am J Med,1996,100(6):52-59.
5Thornsberry C,Yee YC.Comparative activity of eight antimicrobiol agents against clinical bacterial isolates from the United States measured by two methods[J].Am J Med,1996,100(6):26-38.
6Sanders CC.β-lactamases of gram-negative bacteria:new challeng es for new drugs[J].Clin Infect Dis,1992,14(5):1089-1099.
6Reynolds CA, Finkelstein JA, Ray GT, et al. Attributable healthcare utilization and cost of pneumonia~ue to drug- resistant streptococcus pneumonia: a cost analysis[J]. An- timicrob Resist andlnfect Control, 2014, 3( 1 ) : 1-8.
7Larsen BT, Vaszar LT, Colby TV, et al. Lymphoid hyper- plasia and eosinophilic pneumonia as histologic manifes-tations of amiodarone-induced lung toxicity[J]. Test Site, 2012, 36(4): 509-516.
